GSK Advances BALANCE Trial: New IBS Drug Candidate Moves Through Mid‑Stage Testing

GSK Advances BALANCE Trial: New IBS Drug Candidate Moves Through Mid‑Stage Testing  TipRanks

GlaxoSmithKline is running the BALANCE Phase 2b study to test camlipixant in adults with irritable bowel syndrome with diarrhea or mixed symptoms. The trial aims to see if the drug can ease abdominal symptoms over 26 weeks while staying safe, which could open a new market in a large, often poorly treated gut disorder.

The study tests camlipixant, an oral drug, against placebo. The goal is to reduce bowel discomfort and improve daily life for people with IBS-D and IBS-M, offering a targeted option beyond current general symptom relief.

The trial is randomized, so participants are assigned by chance to camlipixant or placebo. It is double-blind and triple-masked, meaning patients, doctors, and study staff do not know who gets what, and it runs in two parts with dose ranging to find the most effective and safe level.

Study Details